Table 4.

Occurrence of hepatocellular carcinoma (HCC) after direct-acting antiviral (DAA) treatment and sustained virological response (SVR) in patients with previous HCC history [21, 24, 25, 28, 32, 34]

Authors (year) [references]	Total SVR patients (n)	Observation periods (months post-DAA initiation)	Patients with HCC occurrence [n (%)]	Annual incidence of HCC (%/year)
Conti et al. (2016) [21]	53	9	38 (71.6)	95.5
Calleja et al. (2017) [24]	70	12	21 (30)	30.0
Nagata et al. (2017) [28]	77	27.6	22 (28.6)	12.4
Ikeda et al. (2017) [25]	155	12	47 (30.3)	30.3
Ooka et al. (2018) [32]	95	15	24 (25.3)	20.2
Ogawa et al. (2018) [34]	152	17	26 (17.1)	12.1
Total	602	15.4 (9–27.6)	178 (29.6)	33.4 (12.1–95.5)

n number